Contribute Try STAT+ Today

In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years ago by a government agency that ordered Alexion Pharmaceuticals to lower the price of a rare disease medicine and reimburse the government for “excessive” pricing.

The ruling follows a long-running struggle that began after the drug maker six years ago refused to lower its price for Soliris, which, depending upon the disease, costs approximately $400,000 to $560,000 per patient. The Patented Medicine Prices Review Board, which demanded a lower price, also ordered the company to repay sales generated by the drug from 2012 through the first half of 2014.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment